- Déficit Androgénique Lié à l’Âge
- Published:
Traitement androgénique substitutif et cancer prostatique
Androgen replacement therapy and prostatic cancer
Andrologie volume 12, pages 136–137 (2002)
Résumé
Les études épidémiologiques ont montré que le risque de cancer de la prostate n’est pas corrélé au taux sérique de testostérone, les androgènes ne semblent pas pouvoir induire un cancer de la prostate chez l’homme. Par contre, l’apport exogène de testostérone peut démasquer un cancer prostatique jusque là freiné par un hypogonadisme. La détection d’un cancer latent avant le début du traitement doit suivre les règles habituelles fondées sur le toucher rectal et le taux sérique du PSA. Une surveillance semestrielle est justifiée en début de traitement, ensuite, la surveillance doit être annuelle.
Abstract
Epidemiological studies show that the risk of prostate cancer was not related to testosterone blood levels. Androgens do not seem to be able to cause prostatic cancer in men. However, administration of exogenous androgens can unmask a prostatic cancer that was, until then, hidden by hypogonadism. Screening of a latent prostatic cancer before the induction of an androgenic treatment must follow the usual recommendations based on digital rectal examination and PSA level determination. A special attention is to be paid when beginning an androgen replacement therapy with a control at six months; thereafter a follow up including digital rectal examination and PSA must be performed every year.
Références
BEHRE H.M., BOHMEYER J., NIESCHLAG E.: Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin. Endocrinol., 1994, 40: 341–349.
BEHRE H.M., VON ECKARDSTEIN S., KLIESCH S. et al.: Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin. Endocrin., 1999, 50: 629–635.
CARTER H.B., PEARSON J.D., METTER E.J. et al.: Longitudinal evaluation of serum androgen levels in men with or without prostate cancer. Prostate, 1995, 27: 25–31.
CURRAN M.J., BIHRLE W.: Dramatic rise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology, 1999, 53: 423–424.
HULKA B.S., HAMMOND J.F., DIFERNANDO G. et al.: Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate, 1987, 11: 171–182.
ISAACS J.T.: Role of androgens in normal and malignant growth of the prostate. In: Bhasin S. ed. Pharmacology, Biology, and Clinical applications of Androgens. New York, Wiley- Liss, 1995: 95–100.
JACKSON J.A., WAXMAN J., SPIEKERMAN A.M.: Prostatic complications of testosterone replacement therapy. Arch. Intern. Med., 1989, 149: 2365–2366.
MEIKLE A.W., ARVER S. DOBS A.S. et al.: Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology, 1997, 49: 191–196.
MONTIE J.E., PIENTA K.J.: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 1994, 43: 892–899.
NOBLE R.L.: Development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 1977, 37: 1929–1933.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flam, T. Traitement androgénique substitutif et cancer prostatique. Androl. 12, 136–137 (2002). https://doi.org/10.1007/BF03034959
Issue Date:
DOI: https://doi.org/10.1007/BF03034959